How much does Tuoyi (Toripalimab Injection) Cost& price without insurance in China?

Tuoyi® is the Chinese commercial brand name of Toripalimab Injection, a humanized anti-PD-1 monoclonal antibody developed by Shanghai Junshi Biosciences. It blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, restoring the immune system’s ability to recognize and kill tumor cells.

Main Indications
Treatment of unresectable or metastatic melanoma that has failed prior systemic therapy.
Treatment of recurrent or metastatic nasopharyngeal carcinoma, urothelial carcinoma, and multiple advanced/metastatic solid tumors after failure of prior systemic therapies.
First-line combination treatment for extensive-stage small cell lung cancer and advanced gastric cancer.

Common Side Effects
Common mild adverse reactions: Fatigue, fever, rash, pruritus, hypothyroidism, and infusion-related reactions.
Laboratory abnormalities: Decreased white blood cell count, decreased lymphocyte count, and elevated liver enzymes.
Severe but uncommon risks: Immune-related pneumonitis, immune-related hepatitis, severe colitis, and endocrine immune-related adverse events.

Approval Status in China
Tuoyi® (Toripalimab Injection, 240mg/6mL) was officially approved for marketing in China in 2018. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.

Buy Tuoyi (Toripalimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.